Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The G1/S Specific Cyclin D2 Is a Regulator of HIV-1 Restriction in Non-proliferating Cells

  • Badia, Roger|||0000-0003-3982-7577
  • Pujantell, Maria|||0000-0002-9471-5853
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • Puig Reixach, Maria Teresa|||0000-0003-1402-7653
  • Torres Torronteras, Javier
  • Martí, Ramon A.|||0000-0002-8273-9540
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Ampudia Carrasco, Rosa María|||0000-0002-0734-0433
  • Vives Pi, Marta|||0000-0003-3735-0779
  • Este, José|||0000-0002-1436-5823
  • Ballana, Ester|||0000-0002-5215-7363
Macrophages are a heterogeneous cell population strongly influenced by differentiation stimuli that become susceptible to HIV-1 infection after inactivation of the restriction factor SAMHD1 by cyclin-dependent kinases (CDK). Here, we have used primary human monocyte-derived macrophages differentiated through different stimuli to evaluate macrophage heterogeneity on cell activation and proliferation and susceptibility to HIV-1 infection. Stimulation of monocytes with GM-CSF induces a non-proliferating macrophage population highly restrictive to HIV-1 infection, characterized by the upregulation of the G1/S-specific cyclin D2, known to control early steps of cell cycle progression. Knockdown of cyclin D2, enhances HIV-1 replication in GM-CSF macrophages through inactivation of SAMHD1 restriction factor by phosphorylation. Co-immunoprecipitation experiments show that cyclin D2 forms a complex with CDK4 and p21, a factor known to restrict HIV-1 replication by affecting the function of the downstream cascade that leads to SAMHD1 deactivation. Thus, we demonstrate that cyclin D2 acts as regulator of cell cycle proteins affecting SAMHD1-mediated HIV-1 restriction in non-proliferating macrophages.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Pharmacological modulation of SAMHD1 activity by CDK4/6 inhibitors improves anticancer therapy

  • Castellví, Marc
  • Felip, Eudald|||0000-0002-3812-1313
  • Ezeonwumelu, I.J.|||0000-0003-4007-2212
  • Badia, Roger|||0000-0003-3982-7577
  • García Vidal, Edurne|||0000-0003-0698-8710
  • Pujantell, Maria|||0000-0002-9471-5853
  • Gutiérrez-Chamorro, Lucía|||0000-0002-7649-951X
  • Teruel, Iris|||0000-0002-5563-6562
  • Martínez Cardús, Anna|||0000-0002-3937-8794
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • Margelí, Mireia|||0000-0003-3594-4530
  • Ballana, Ester|||0000-0002-5215-7363
Sterile alpha motif and histidine-aspartic acid domain-containing protein 1 (SAMHD1) is a dNTP triphosphohydrolase involved in the regulation of the intracellular dNTP pool, linked to viral restriction, cancer development and autoimmune disorders. SAMHD1 function is regulated by phosphorylation through a mechanism controlled by cyclin-dependent kinases and tightly linked to cell cycle progression. Recently, SAMHD1 has been shown to decrease the efficacy of nucleotide analogs used as chemotherapeutic drugs. Here, we demonstrate that SAMHD1 can enhance or decrease the efficacy of various classes of anticancer drug, including nucleotide analogues, but also anti-folate drugs and CDK inhibitors. Importantly, we show that selective CDK4/6 inhibitors are pharmacological activators of SAMHD1 that act by inhibiting its inactivation by phosphorylation. Combinations of a CDK4/6 inhibitor with nucleoside or folate antimetabolites potently enhanced drug efficacy, resulting in highly synergic drug combinations (CI < 0.04). Mechanistic analyses reveal that cell cycle-controlled modulation of SAMHD1 function is the central process explaining changes in anticancer drug efficacy, therefore providing functional proof of the potential of CDK4/6 inhibitors as a new class of adjuvants to boost chemotherapeutic regimens. The evaluation of SAMHD1 expression in cancer tissues allowed for the identification of cancer types that would benefit from the pharmacological modulation of SAMHD1 function. In conclusion, these results indicate that the modulation of SAMHD1 function may represent a promising strategy for the improvement of current antimetabolite-based treatments.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

RNA editing by ADAR1 regulates innate and antiviral immune functions in primary macrophages

  • Pujantell, Maria|||0000-0002-9471-5853
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • Badia, Roger|||0000-0003-3982-7577
  • Castellví, Marc
  • García Vidal, Edurne|||0000-0003-0698-8710
  • Sirera, Guillem|||0000-0003-4014-9355
  • Puig Oliva, Teresa
  • Ramirez Soto, Cristina
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Este, José|||0000-0002-1436-5823
  • Ballana, Ester|||0000-0002-5215-7363
ADAR1-dependent A-to-I editing has recently been recognized as a key process for marking dsRNA as self, therefore, preventing innate immune activation and affecting the development and resolution of immune-mediated diseases and infections. Here, we have determined the role of ADAR1 as a regulator of innate immune activation and modifier of viral susceptibility in primary myeloid and lymphoid cells. We show that ADAR1 knockdown significantly enhanced interferon, cytokine and chemokine production in primary macrophages that function as antiviral paracrine factors, rendering them resistant to HIV-1 infection. ADAR1 knockdown induced deregulation of the RLRs-MAVS signaling pathway, by increasing MDA5, RIG-I, IRF7 and phospho-STAT1 expression, an effect that was partially rescued by pharmacological blockade of the pathway. In summary, our results demonstrate a role of ADAR1 in regulating innate immune function in primary macrophages, suggesting that macrophages may play an essential role in disease associated to ADAR1 dysfunction. We also show that viral inhibition is exclusively dependent on innate immune activation consequence of ADAR1 knockdown, pointing towards ADAR1 as a potential target to boost antiviral immune response.